N. De Schrevel

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

John L. Perez, Ping Li, E. Aris, 2020, BMC Infectious Diseases.

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

John L. Perez, Ping Li, E. Aris, 2020, Human vaccines & immunotherapeutics.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

M. Ison, J. Langley, L. Cámpora, 2023, The New England journal of medicine.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains

Edison Ong, N. Dezutter, M. David, 2023, Science Translational Medicine.

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.

M. Haranaka, N. Mesaros, M. David, 2023, Respiratory investigation.

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

M. Ison, J. Langley, F. Martinón-Torres, 2022, Open Forum Infectious Diseases.